{"success":true,"data":{"pressRelease":{"id":"142424","rtpr_id":"nGNE4lZ7fb-20260914","ticker":"EVAX","exchange":"NASDAQ","all_tickers":["EVAX"],"title":"Evaxion applies its AI-Immunology™ platform in autoimmune diseases","author":"Globe Newswire","published_at":"2026-09-14T12:00:00.079Z","article_body":"* Autoimmune diseases are characterized by high unmet medical need with\nmost current treatments only addressing symptoms. Evaxion will apply\nAI-Immunology™ to target underlying pathologies\n* The unique capabilities of AI-Immunology™ could potentially help develop\nnew treatments with higher efficacy and less side effects than current\ntreatments\n* Initial experimental data will be presented at the Protein & Antibody\nEngineering Summit (PEGS) Europe taking place in Lisbon, Portugal, on November\n18, 2026\nCOPENHAGEN, Denmark, September 14, 2026 - Evaxion A/S (NASDAQ: EVAX)\n(“Evaxion”), a clinical-stage TechBio company developing novel vaccines\nwith its pioneering AI- Immunology™ platform, has begun the application of\nthe platform in autoimmune diseases thereby expanding the company’s\ntherapeutic focus and achieving another company milestone for 2026.\n\nWe are now conducting experimental testing of two novel AI-Immunology™\n-based treatment concepts for autoimmune diseases. Both concepts could\npotentially offer higher efficacy and less side effects than currently\navailable treatments as AI-Immunology™ has unique capabilities in addressing\nunderlying disease pathologies with very high specificity.\n\nAI-Immunology™ enables development of several novel therapeutic concepts\nfocusing on disease modification. This carries substantial opportunities as\nautoimmune diseases are characterized by high unmet medical need with few\ntreatment approaches focused on the underlying disease and offer significant\npartnership potential across all stages of drug development.\n\n“We are very excited to apply AI-Immunology™ in a new disease area and\nvalidate these novel concepts, which could potentially target underlying\ndisease biology rather than just symptoms. Autoimmune diseases can be severely\ndebilitating and even lethal placing a massive burden on patients, relatives\nand society. With AI-Immunology™ we have unique opportunities to potentially\nimprove treatment options in this area,” says Birgitte Rønø, CSO and COO\nof Evaxion.\n\nTesting two different concepts \nSpecifically, Evaxion is now testing a tolerogenic vaccine concept and an\nautoantibody binder concept. Data from the ongoing experiments will be\npresented at the Protein & Antibody Engineering Summit (PEGS) Europe taking\nplace in Lisbon, Portugal, on November 18, 2026.\n\nThe tolerogenic approach involves vaccination with T-cell epitopes and\nco-delivery of immune modulators that direct the immune system to tolerance.\nAI-Immunology™ has unique capabilities in finding and prioritizing the best\nepitopes.\n\nThe autoantibody binder concept utilizes an antigen construct that captures\nautoantibodies, which are the main pathogenic drivers in many autoimmune\ndiseases. Autoantibodies bind to 1 normal tissue causing tissue damage and/or\nblocking of key physiological functions. Thus, clearing of these\nautoantibodies is expected to treat the diseases.\n\nContact information \nEvaxion A/S \nMads Kronborg \nVice President, Investor Relations & Communication \n+45 53 54 82 96 \nmak@evaxion.ai\n\nAbout Evaxion \nEvaxion is a pioneering TechBio company based upon its proprietary, clinically\nvalidated and scalable AI platform, AI-Immunology™. The platform harnesses\nthe power of artificial intelligence to decode the human immune system and\ndevelop novel drug candidates for cancer and infectious diseases. \n\nWith AI-Immunology™ we conduct rapid, efficient and high-quality target\ndiscovery, drug design and development. Our team of +40 experts covers the\nentire value chain from target discovery to clinical development.\n\nWe have developed a clinical pipeline of both personalized and off-the-shelf\ncancer vaccine candidates as well as prophylactic vaccine candidates for\ninfectious diseases. All our candidates address high unmet medical needs,\nreflecting our commitment to transforming patients’ lives by providing\ninnovative and targeted treatment options.\n\nFor more information about Evaxion, AI-Immunology™ and our pipeline, please\nvisit our website\n(https://www.globenewswire.com/Tracker?data=ewfqIt3piFu2VfKeHPVPTMzLNYIOG50RjqPgnjcjdrVLGPO-plS8a8cMBfFb7e9A3oTQ0LOPCB0higKlwmpw4A==).\n\nForward-looking statement \nThis announcement contains forward-looking statements within the meaning of\nSection 27A of the Securities Act of 1933, as amended, and Section 21E of the\nSecurities Exchange Act of 1934, as amended. The words “target,”\n“believe,” “expect,” “hope,” “aim,” “intend,” “may,”\n“might,” “anticipate,” “contemplate,” “continue,”\n“estimate,” “plan,” “potential,” “predict,” “project,”\n“will,” “can have,” “likely,” “should,” “would,”\n“could,” and other words and terms of similar meaning identify\nforward-looking statements. Actual results may differ materially from those\nindicated by such forward-looking statements as a result of various factors,\nincluding, but not limited to, risks related to: our financial condition and\nneed for additional capital; our development work; cost and success of our\nproduct development activities and preclinical and clinical trials;\ncommercializing any approved pharmaceutical product developed using our AI\nplatform technology, including the rate and degree of market acceptance of our\nproduct candidates; our dependence on third parties including for conduct of\nclinical testing and product manufacture; our inability to enter into\npartnerships; government regulation; protection of our intellectual property\nrights; employee matters and managing growth; our ADSs and ordinary shares,\nthe impact of international economic, political, legal, compliance, social and\nbusiness factors, including inflation, and the effects on our business from\nother significant geopolitical and macro-economic events; and other\nuncertainties affecting our business operations and financial condition. For a\nfurther 2 discussion of these risks, please refer to the risk factors included\nin our most recent Annual Report on Form 20-F and other filings with the US\nSecurities and Exchange Commission (SEC), which are available at www.sec.gov.\nWe do not assume any obligation to update any forward-looking statements\nexcept as required by law.","article_body_html":"","raw_payload":{"data":{"id":"nGNE4lZ7fb-20260914","title":"Evaxion applies its AI-Immunology™ platform in autoimmune diseases","author":"Globe Newswire","ticker":"EVAX","created":"2026-09-14T12:00:00.079Z","tickers":["EVAX"],"exchange":"NASDAQ","article_body":"* Autoimmune diseases are characterized by high unmet medical need with\nmost current treatments only addressing symptoms. Evaxion will apply\nAI-Immunology™ to target underlying pathologies\n* The unique capabilities of AI-Immunology™ could potentially help develop\nnew treatments with higher efficacy and less side effects than current\ntreatments\n* Initial experimental data will be presented at the Protein & Antibody\nEngineering Summit (PEGS) Europe taking place in Lisbon, Portugal, on November\n18, 2026\nCOPENHAGEN, Denmark, September 14, 2026 - Evaxion A/S (NASDAQ: EVAX)\n(“Evaxion”), a clinical-stage TechBio company developing novel vaccines\nwith its pioneering AI- Immunology™ platform, has begun the application of\nthe platform in autoimmune diseases thereby expanding the company’s\ntherapeutic focus and achieving another company milestone for 2026.\n\nWe are now conducting experimental testing of two novel AI-Immunology™\n-based treatment concepts for autoimmune diseases. Both concepts could\npotentially offer higher efficacy and less side effects than currently\navailable treatments as AI-Immunology™ has unique capabilities in addressing\nunderlying disease pathologies with very high specificity.\n\nAI-Immunology™ enables development of several novel therapeutic concepts\nfocusing on disease modification. This carries substantial opportunities as\nautoimmune diseases are characterized by high unmet medical need with few\ntreatment approaches focused on the underlying disease and offer significant\npartnership potential across all stages of drug development.\n\n“We are very excited to apply AI-Immunology™ in a new disease area and\nvalidate these novel concepts, which could potentially target underlying\ndisease biology rather than just symptoms. Autoimmune diseases can be severely\ndebilitating and even lethal placing a massive burden on patients, relatives\nand society. With AI-Immunology™ we have unique opportunities to potentially\nimprove treatment options in this area,” says Birgitte Rønø, CSO and COO\nof Evaxion.\n\nTesting two different concepts \nSpecifically, Evaxion is now testing a tolerogenic vaccine concept and an\nautoantibody binder concept. Data from the ongoing experiments will be\npresented at the Protein & Antibody Engineering Summit (PEGS) Europe taking\nplace in Lisbon, Portugal, on November 18, 2026.\n\nThe tolerogenic approach involves vaccination with T-cell epitopes and\nco-delivery of immune modulators that direct the immune system to tolerance.\nAI-Immunology™ has unique capabilities in finding and prioritizing the best\nepitopes.\n\nThe autoantibody binder concept utilizes an antigen construct that captures\nautoantibodies, which are the main pathogenic drivers in many autoimmune\ndiseases. Autoantibodies bind to 1 normal tissue causing tissue damage and/or\nblocking of key physiological functions. Thus, clearing of these\nautoantibodies is expected to treat the diseases.\n\nContact information \nEvaxion A/S \nMads Kronborg \nVice President, Investor Relations & Communication \n+45 53 54 82 96 \nmak@evaxion.ai\n\nAbout Evaxion \nEvaxion is a pioneering TechBio company based upon its proprietary, clinically\nvalidated and scalable AI platform, AI-Immunology™. The platform harnesses\nthe power of artificial intelligence to decode the human immune system and\ndevelop novel drug candidates for cancer and infectious diseases. \n\nWith AI-Immunology™ we conduct rapid, efficient and high-quality target\ndiscovery, drug design and development. Our team of +40 experts covers the\nentire value chain from target discovery to clinical development.\n\nWe have developed a clinical pipeline of both personalized and off-the-shelf\ncancer vaccine candidates as well as prophylactic vaccine candidates for\ninfectious diseases. All our candidates address high unmet medical needs,\nreflecting our commitment to transforming patients’ lives by providing\ninnovative and targeted treatment options.\n\nFor more information about Evaxion, AI-Immunology™ and our pipeline, please\nvisit our website\n(https://www.globenewswire.com/Tracker?data=ewfqIt3piFu2VfKeHPVPTMzLNYIOG50RjqPgnjcjdrVLGPO-plS8a8cMBfFb7e9A3oTQ0LOPCB0higKlwmpw4A==).\n\nForward-looking statement \nThis announcement contains forward-looking statements within the meaning of\nSection 27A of the Securities Act of 1933, as amended, and Section 21E of the\nSecurities Exchange Act of 1934, as amended. The words “target,”\n“believe,” “expect,” “hope,” “aim,” “intend,” “may,”\n“might,” “anticipate,” “contemplate,” “continue,”\n“estimate,” “plan,” “potential,” “predict,” “project,”\n“will,” “can have,” “likely,” “should,” “would,”\n“could,” and other words and terms of similar meaning identify\nforward-looking statements. Actual results may differ materially from those\nindicated by such forward-looking statements as a result of various factors,\nincluding, but not limited to, risks related to: our financial condition and\nneed for additional capital; our development work; cost and success of our\nproduct development activities and preclinical and clinical trials;\ncommercializing any approved pharmaceutical product developed using our AI\nplatform technology, including the rate and degree of market acceptance of our\nproduct candidates; our dependence on third parties including for conduct of\nclinical testing and product manufacture; our inability to enter into\npartnerships; government regulation; protection of our intellectual property\nrights; employee matters and managing growth; our ADSs and ordinary shares,\nthe impact of international economic, political, legal, compliance, social and\nbusiness factors, including inflation, and the effects on our business from\nother significant geopolitical and macro-economic events; and other\nuncertainties affecting our business operations and financial condition. For a\nfurther 2 discussion of these risks, please refer to the risk factors included\nin our most recent Annual Report on Form 20-F and other filings with the US\nSecurities and Exchange Commission (SEC), which are available at www.sec.gov.\nWe do not assume any obligation to update any forward-looking statements\nexcept as required by law."},"type":"article","timestamp":"2026-09-14T12:00:00.263826063Z","server_sent_at_ms":1789387200263},"received_at":"2026-09-14T12:00:00.375Z","source_url":null},"analysis":{"id":"131259","press_release_id":"142424","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["Expansion into autoimmune diseases is preclinical/experimental — no human or efficacy data yet","First data not expected until the PEGS Europe presentation on November 18, 2026","Company risk language reiterates financial condition and need for additional capital, typical of a clinical-stage micro-cap"],"eventType":"operations_update","narrative":"Evaxion A/S (NASDAQ: EVAX) has begun applying its AI-Immunology™ platform to autoimmune diseases, expanding the clinical-stage TechBio's therapeutic focus beyond cancer and infectious disease vaccines.\n\nThe company is conducting experimental testing of two novel concepts — a tolerogenic vaccine that directs the immune system toward tolerance and an autoantibody binder designed to clear pathogenic autoantibodies — with initial data to be presented at PEGS Europe in Lisbon on November 18, 2026.\n\nManagement frames the expansion as addressing high unmet medical need with potential for higher efficacy and fewer side effects than current symptom-focused treatments, and cites significant partnership potential across all stages of drug development, though the work remains preclinical with no efficacy data yet.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Evaxion extends its AI platform into autoimmune disease — early-stage optionality, but watch the PEGS Europe data drop on November 18 before drawing conclusions."},"keyFigures":{"customDimensions":{"data_venue":"Protein & Antibody Engineering Summit (PEGS) Europe, Lisbon, Portugal","first_data_date":"November 18, 2026","treatment_concepts_tested":2}},"quotedText":"We are very excited to apply AI-Immunology™ in a new disease area and\nvalidate these novel concepts, which could potentially target underlying\ndisease biology rather than just symptoms.","namedEntities":{"people":[{"name":"Birgitte Rønø","role":"CSO and COO of Evaxion"},{"name":"Mads Kronborg","role":"Vice President, Investor Relations & Communication"}],"products":["AI-Immunology™","tolerogenic vaccine concept","autoantibody binder concept"],"companies":[{"name":"Evaxion A/S","ticker":"EVAX","relationship":"filer"},{"name":"Protein & Antibody Engineering Summit (PEGS) Europe","relationship":"conference where data will be presented"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Evaxion is expanding its AI-Immunology platform into autoimmune diseases with two preclinical concepts under experimental testing — a strategic milestone, but with no efficacy data, no financial figures, and first data not due until the PEGS Europe presentation on November 18, 2026."},"tickerRelevance":{"others":[],"primary":"EVAX"},"globalImportance":18,"audienceRelevance":12,"eventTypeSecondary":[],"importanceComponents":{"dataStatus":"preclinical, no data disclosed","tickerTier":"micro-cap","eventGravity":"platform-expansion-announcement","issuerAuthored":true,"upcomingCatalyst":"PEGS Europe data presentation 2026-11-18"}},"event_type":"operations_update","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Evaxion A/S (NASDAQ: EVAX) has begun applying its AI-Immunology™ platform to autoimmune diseases, expanding the clinical-stage TechBio's therapeutic focus beyond cancer and infectious disease vaccines.\n\nThe company is conducting experimental testing of two novel concepts — a tolerogenic vaccine that directs the immune system toward tolerance and an autoantibody binder designed to clear pathogenic autoantibodies — with initial data to be presented at PEGS Europe in Lisbon on November 18, 2026.\n\nManagement frames the expansion as addressing high unmet medical need with potential for higher efficacy and fewer side effects than current symptom-focused treatments, and cites significant partnership potential across all stages of drug development, though the work remains preclinical with no efficacy data yet.","key_figures":{"customDimensions":{"data_venue":"Protein & Antibody Engineering Summit (PEGS) Europe, Lisbon, Portugal","first_data_date":"November 18, 2026","treatment_concepts_tested":2}},"named_entities":{"people":[{"name":"Birgitte Rønø","role":"CSO and COO of Evaxion"},{"name":"Mads Kronborg","role":"Vice President, Investor Relations & Communication"}],"products":["AI-Immunology™","tolerogenic vaccine concept","autoantibody binder concept"],"companies":[{"name":"Evaxion A/S","ticker":"EVAX","relationship":"filer"},{"name":"Protein & Antibody Engineering Summit (PEGS) Europe","relationship":"conference where data will be presented"}],"dollarAmounts":[]},"model_name":"glm-5.3-flash","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-14T12:00:24.968Z","global_importance":18,"audience_relevance":12,"importance_components":{"dataStatus":"preclinical, no data disclosed","tickerTier":"micro-cap","eventGravity":"platform-expansion-announcement","issuerAuthored":true,"upcomingCatalyst":"PEGS Europe data presentation 2026-11-18"}},"durationMs":24505,"modelName":"glm-5.3-flash"}}